read all at
Chinese HFMD vaccine impresses in Phase III
Uncategorized
Comments Off on Chinese HFMD vaccine impresses in Phase III
May 312013
Study: Lilly’s Forteo Increases Bone Mineral Density in Men
drugs
Comments Off on Study: Lilly’s Forteo Increases Bone Mineral Density in Men
May 312013
![FORTEO (teriparatide [rDNA origin]) Structural Formula Illustration](http://images.rxlist.com/images/rxlist/forteo1.gif)
New Data on FORTEO® (teriparatide [rDNA origin] injection) Show Increased Bone Mineral Density in Men with Glucocorticoid-Induced Osteoporosis
http://www.pharmalive.com/study-lillys-forteo-increases-bone-mineral-density-in-men
May 302013
Ensemble Therapeutics to Present Data on IL-17A Inhibitors that are Novel, Oral Macrocycles Against Previously Undruggable Target
drugs
Comments Off on Ensemble Therapeutics to Present Data on IL-17A Inhibitors that are Novel, Oral Macrocycles Against Previously Undruggable Target
May 302013
 |
|
Example of an Ensemblin™
|
Ensemble Therapeutics today announced that preclinical data showing the advantages of its Ensemblins, novel macrocyclic compounds against challenging drug targets, will be presented at the 245th American Chemical Society (ACS) National Meeting …
Ensemblins™ are a new class of synthetic macrocycles developed by Ensemble using its proprietary chemistry platforms, including DNA-Programmed Chemistry. Macrocyclic rings are found in many natural product-based drugs and bestow favorable pharmaceutical properties and powerful protein surface binding properties upon such drugs. Thus, macrocycles are uniquely suited to address many protein targets that cannot be modulated effectively by traditional small molecule pharmaceutical compounds. Macrocycles have been challenging to synthesize in large numbers and this has constrained their wider use in the industry. By extending beyond the limits of traditional small molecule drug discovery, Ensemble’s platform provides unmatched capabilities to successfully and reliably generate millions of macrocyclic Ensemblins as drug candidates, larger than any collection previously synthesized in the pharmaceutical industry
Predicting Drug Toxicity in Humans
TOXICITY
Comments Off on Predicting Drug Toxicity in Humans
May 302013
Predicting Drug Toxicity in Humans
Genetic Engineering News
“A major challenge of drug safety testing is that preclinical studies with laboratory animals are not always predictive of human safety,” said Albert P. Li, Ph.D., president and CEO of In Vitro ADMET Laboratories. Dr. Li cited the frequent clinical ………………………….http://www.genengnews.com/gen-articles/predicting-drug-toxicity-in-humans/4815/
Encouraging Data from Alkermes, ALKS 3831 – Analyst Blog
drugs
Comments Off on Encouraging Data from Alkermes, ALKS 3831 – Analyst Blog
May 302013
NASDAQ
Data was presented at the 53rd annual meeting of the New Clinical Drug Evaluation Unit (NCDEU) held in the US. ALKS 3831 … Encouraged by the positive results of the phase I study, Alkermes expects to initiate a phase II dose-ranging study on ALKS 3831.http://www.nasdaq.com/article/encouraging-data-from-alkermes-analyst-blog-cm249504
Alkermes plc recently presented encouraging data from a phase I study, which evaluated its schizophrenia candidate, ALKS 3831. Data was presented at the 53rd annual meeting of the New Clinical Drug Evaluation Unit (NCDEU) held in the US. ALKS 3831 is a combination of ALKS 33, and Eli Lilly and Company’ s antipsychotic drug Zyprexa (olanzapine).
A Fundamental Take On Alkermes’ Turnaround Story
drugs
Comments Off on A Fundamental Take On Alkermes’ Turnaround Story
May 302013
A Fundamental Take On Alkermes’ Turnaround Story
Seeking Alpha
These products are for multiple sclerosis complication, Opioid dependence, alcohol dependence, schizophrenia and Type 2 diabetes. The drugs are in the early phase of the product cycle, and hence the possibility of faster growth in revenues is …http://seekingalpha.com/article/1467401-a-fundamental-take-on-alkermes-turnaround-story?source=google_news
The product pipeline consists of drugs like ZOHYDRO ER (pain) for which patent has been filed, and other drug candidates like Exenatide (Type 2 diabetes), Aripiprazole Lauroxil (schizophrenia), INVEGA SUSTENNA (schizophrenia), ALKS 5461 (major depressive disorder), and ALKS 3831 (schizophrenia), which are in phase 2/phase 3 of trial.
Silence Starts Phase Ia/IIb Trial of Cancer Drug as It Looks to Balance Pipeline
cancer
Comments Off on Silence Starts Phase Ia/IIb Trial of Cancer Drug as It Looks to Balance Pipeline
May 302013
Silence Starts Phase Ia/IIb Trial of Cancer Drug as It Looks to Balance Pipeline
Silence Starts Phase Ia/IIb Trial of Cancer Drug as It Looks to Balance Pipeline GenomeWeb If no toxicity is observed, the phase IIa arm of the trial will begin with pancreatic cancer patients receiving the two drugs once a week for three consecutive weeks, with no treatment on the fourth week. This dosing schedule will continue in … http://www.genomeweb.com/rnai/silence-starts-phase-iaiib-trial-cancer-drug-it-looks-balance-pipeline
Iclusig (ponatinib) VERSUS Gleevec (imatinib)
drugs
Comments Off on Iclusig (ponatinib) VERSUS Gleevec (imatinib)
May 302013
3 Innovative Biotech Companies With Promising Cancer Therapies
Seeking Alpha
The global, Phase III EPIC trial which compares Iclusig to Novartis’ blockbuster drug Gleevec (imatinib) in patients with newly diagnosed CML, is advancing. The company expects to reach full patient enrollment in the fourth quarter of 2013 …
May 292013
3 Biopharma Runners With Fuel in the Tank
Investorplace.com
Gilead Sciences (GILD) stock recently set a new all-time high after reporting that in a recent Phase 2 study, its oral drug idelalisib successfully drove the life-threatening chronic lymphocytic leukemia (CLL) into remission. The regimen produced a 97% …
Gilead Sciences (GILD) stock recently set a new all-time high after reporting that in a recent Phase 2 study, its oral drug idelalisib successfully drove the life-threatening chronic lymphocytic leukemia (CLL) into remission. The regimen produced a 97% response rate, with 93% of trial patients surviving progression-free at the end of two years. CLL, which produces too many mature white cells, is the second most common form of leukemia in the U.S.
http://investorplace.com/2013/05/3-biopharma-runners-with-fuel-in-the-tank/